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The dystroglycanopathies comprise a clinically and genetically heterogeneous group of muscular dystro-
phies characterized by deficient glycosylation of a-dystroglycan. Mutations in the fukutin (FKTN) gene
have primarily been identified among patients with classic Fukuyama congenital muscular dystrophy
(FCMD), a severe form of dystroglycanopathy characterized by CMD, cobblestone lissencephaly and ocu-
lar defects. We describe two brothers of Caucasian and Japanese ancestry with normal intelligence and
limb-girdle muscular dystrophy (LGMD) due to compound heterozygous FKTN mutations. Muscle biopsy
showed a dystrophy with selectively reduced a-dystroglycan glycoepitope immunostaining. Immuno-
blots revealed hypoglycosylation of a-dystroglycan and loss of laminin binding. FKTN gene sequencing
identified two variants: c.340G>A and c.527T>C, predicting missense mutations p.A114T and p.F176S,
respectively. Our results provide further evidence for ethnic and allelic heterogeneity and the presence
of milder phenotypes in FKTN-dystroglycanopathy despite a substantial degree of a-dystroglycan hypo-
glycosylation in skeletal muscle.
 2009 Elsevier B.V. All rights reserved.1. Introduction
Multiple forms of muscular dystrophy are now known to be
caused by defects in the O-linked glycosylation of a-dystroglycan.
These dystroglycanopathies span a spectrum of phenotypes from
Walker–Warburg syndrome (WWS; OMIM 236670; characterized
by severe congenital muscular dystrophy, retinal and anterior
chamber eye abnormalities, cobblestone lissencephaly, and hydro-
cephalus) to mild, adult onset LGMD [1]. Included in this group of
disorders is Fukuyama congenital muscular dystrophy (FCMD;
OMIM 253800). Patients with typical FCMD display dystrophic
changes in skeletal muscle, structural brain malformations, and
severe ocular abnormalities. Most patients are never able to walk
independently and have moderate to severe cognitive delay. The
average life span is less than 20 years [2,3].
The gene implicated in FCMD, FKTN, located on chromosome
9q31, was identified in 1998 by Kobayashi et al. [4]. A 3 kb retro-
transposon insertion mutation in the 30-untranslated region of this
gene, descended from a single ancestor, is responsible for the
relatively high prevalence of the disorder in Japan [4]. Among thell rights reserved.
: +1 714 532 8362.
I, USA.first cases of FKTN-dystroglycanopathy reported outside of Japan
are two Turkish patients, both with homozygous null mutations,
who suffered from a severe, WWS-like phenotype with early
lethality [5,6].
Recently, milder cases of muscular dystrophy associated with
FKTN gene mutations have been reported in both Japanese and
non-Japanese populations. In 2006, Murakami et al. reported on
six Japanese patients, all of whom were compound heterozygotes
for the FKTN founder mutation and a point mutation in this gene,
with minimal muscle weakness, normal intellect and dilated car-
diomyopathy [7]. Other recent papers by Godfrey et al. reported
on five non-Japanese children from three families with normal
intelligence and a limb-girdle phenotype, caused by heterozygous
point mutations in the FKTN gene [8,9]. We report an additional
two brothers with a LGMD phenotype, and describe one previously
unreported mutation in the FKTN gene.
2. Patients and methods
2.1. Patients
Two brothers with a history of elevated serum creatine kinase
(CK) ranging from 1865 to 12,131 IU/L (nl 41–277 IU/L) and mild
muscle weakness from a non-consanguineous family were studied.
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histopathology and immunofluorescence suggestive of an a-dys-
troglycan glycosylation abnormality.
2.2. Histopathology and immunohistochemistry
Cryosections of skeletal muscle were stained with hematoxylin
and eosin (H&E) and underwent standard immunofluorescence
staining using a panel of antibodies directed at muscular dystro-
phy-associated proteins [10]. Fluorescence microscopy was
performed for dystrophin (Developmental Studies Hybridoma
Bank, rod domain antibody 6A9), b-dystroglycan (Novocastra),
and a-dystroglycan (glycoepitope antibody IIH6) [10]. Immunoflu-
orescence was also performed with the core a-dystroglycan
antibody, GT20ADG [11].
2.3. Western blots and laminin overlay
Frozen muscle was homogenized and glycoproteins enriched by
WGA according to the protocol published in Michele et al. [11].
Immunoblots were performed with the a-dystroglycan glycoepi-
tope antibody IIH6, the a-dystroglycan core antibody GT20ADG,
and the b-dystroglycan antibody AP83. Laminin overlays utilized
mouse Engelbreth–Holm–Swarm (EHS) laminin and anti-laminin
antibody (Sigma) [11].
2.4. Mutation analysis
Genomic DNA was extracted from whole blood using Puregene
reagents (Gentra Systems, Inc., Minneapolis, MN). Amplification of
genomic DNA for FKTN sequence analysis was performed in 50 lL
reaction volumes containing 1 PCR buffer (Qiagen), 1.5 mM
MgCl2, 200 lM dNTPs, 1.0 lM each of FKTN forward and reverse
primers, 1 U of taq polymerase (Qiagen) and 150 ng of patient
DNA. Cycling parameters were as follows: 5 min at 95 C; followed
by 10 cycles of 30 s at 95 C, 30 s at 65 C with decreases of 0.5 C/
cycle, 60 s at 72 C; followed by 25 cycles of 30 s at 95 C, 30 s at
60 C, 60 s at 72 C; followed by 7 min at 72 C.
Sequence analysis of FKTN exons 2–10 was performed by cycle
sequencing 5 ng of template in 10 lL reactions with Big Dye Termi-
nator 3.1 (Applied Biosystems Inc., Foster City, CA) as recom-
mended by the manufacturer. An ABI3130 instrument and
Seqscape software (ABI) was used for analysis. Patient results were
compared to reference sequence NM_006731.2 (UCSC Genome
Browser, NCBI Build 36.1) to identify sequence variations.
Additionally, each of the five genes known to be associated with
a-dystroglycanopathy, FKRP, POMT1, POMT2, POMGnT1, and LARGE,
was studied. The coding exons and 50–100 bp of flanking noncod-
ing sequence were amplified and bi-directionally sequenced using
standard procedures. The patient’s sequence was then compared
to the following reference sequences: NM_024301 (FKRP),
NM_007171.2 (POMT1), NM_013382 (POMT2), NM_017739 (POM-
GnT1), NC_000022.9 (LARGE) (UCSC Genome Browser, NCBI Build
36.1).3. Results
3.1. Clinical findings
Patient 1 is a boy who was born at full term after an uneventful
pregnancy to a healthy mother of Japanese ancestry and healthy
father of Caucasian ancestry. His early development was normal.
Around 9 months of age, the child’s growth, which had been
slightly below the 5th percentile since birth, began to plateau. At
13 months of age, he was seen in the metabolic clinic for failureto thrive and elevated transaminases. His height and weight were
both below the 3rd percentile. Head circumference was between
the 25th and 50th percentiles. Physical exam was normal, includ-
ing muscle tone, strength and deep tendon reflexes. Initial work-
up was remarkable for an elevated CK of 3110 IU/L. ALT and AST
were slightly increased at 96 U/L (nl 9–80 U/L) and 77 U/L (nl 1–
55 U/L), respectively. An acylcarnitine profile, carnitine levels and
urine organic acids were normal. At 17 months of age, the patient’s
CK remained elevated (1865 IU/L). Both parents had normal CK lev-
els. Muscle weakness was first noted at 21 months of age and by
24 months, physical exam was remarkable for incipient pectus
excavatum, modified Gowers’ maneuver and decreased deep
tendon reflexes. There was no evidence of calf hypertrophy and
cognitive and motor development continued to be normal. The
patient was referred for muscle biopsy. Cardiac and ophthalmology
evaluations were normal. Calf hypertrophy was evident by 2 years,
9 months of age. At 5 years of age, the patient’s physical exam was
unchanged and his cognitive and social development remained
normal. He has been hospitalized once for pneumonia. CK levels
have ranged between 1865 and 12,131 IU/L.
Patient 2 is the older brother of patient 1. He was referred at
4 years of age, after his brother’s diagnosis was made. He rolled
over at 6 months, sat up at 8 months and walked at 12 months.
His initial physical exam revealed subtle abnormalities, including
mild hypotonia, decreased muscle strength, calf hypertrophy, par-
tial Gowers’ maneuver and decreased deep tendon reflexes. Head
circumference was between the 25th and 50th percentiles. Cardiac
and ophthalmology exams were normal. At 4 years, 5 months of
age, incipient lumbar lordosis and pectus excavatum were noted.
Follow-up, 6 months later, revealed waddling gait. He was last seen
at 6 years, 11 months of age and was stable. His gait had improved.
CK levels have ranged between 4068 and 9955 U/L. Both brothers
receive physical therapy.
3.2. Histopathology
Small numbers of necrotic and regenerating myofibers, some-
times clustered, were identified in the biopsy from patient 1 per-
formed at age 2. There was a marked degree of variation in fiber
size due to both atrophic and hypertrophic fibers in an intermixed
pattern in association with mild endomysial fibrosis (Fig. 1A). No
lymphocytic inflammation was noted.
3.3. Immunostaining
Immunofluorescence staining showed normal expression of
dystrophin (Fig. 1B), utrophin, spectrin, sarcoglycans, merosin,
and collagen VI (data not shown). b-Dystroglycan also stained nor-
mally (Fig. 1E), while a-dystroglycan staining with glycosylation-
dependent antibodies varied in a mosaic pattern from absent to
nearly normal (IIH6 is shown in Fig. 1D). Immunofluorescence with
the a-dystroglycan core antibody, GT20ADG [11], shows that
a-dystroglycan is present at the sarcolemma of all muscle fibers
(Fig. 1C).
3.4. Western blots and laminin overlay
Immunoblots show less fully glycosylated a-dystroglycan in the
patient compared to control (Fig. 2A); the small amount of func-
tionally glycosylated a-dystroglycan detected in the patient has a
reduced molecular weight compared to control. On the other hand,
b-dystroglycan appears normal (Fig. 2B). Lower molecular weight,
hypoglycosylated a-dystroglycan is revealed in the patient by the
core a-dystroglycan antibody (Fig. 2B). The molecular weight shift
to 90 kDa observed in our patient is similar to that previously
reported in MEB, FCMD, and WWS patients [11,12]. The residual
Fig. 1. Histology and immunofluorescence. Mildly dystrophic histopathology is
evident in the H&E photomicrograph (A); shown here are atrophy, hypertrophy,
muscle fiber regeneration, and mild endomysial fibrosis. a-Dystroglycan ranges
from negative to nearly normal with the glycoepitope antibody IIH6 (D), while
dystrophin (B), a-dystroglycan using the core aDG antibody GT20ADG (C), and b-
dystroglycan (E) stain normally. All images photographed with a 40 objective.
Numbers in the immunofluorescence panels indicate the same muscle fibers in
adjacent cryosections.
Fig. 2. Western blot (A and B) and laminin overlay (C). Control lanes in each blot are
labeled C. Patient lanes are labeled F. Fully glycosylated a-dystroglycan is marked
by black arrowheads. The position of partially glycosylated a-dystroglycan is
marked by white arrowheads. The asterisk is hypoglycosylated a-dystroglycan
detected in the patient by the core antibody. b-Dystroglycan is marked by the black
arrow. Compared to the control, the patient’s muscle shows a reduced amount of
fully glycosylated a-dystroglycan (A), but normal b-dystroglycan (B). However, the
core a-dystroglycan antibody reveals that lower molecular weight a-dystroglycan
is present (B). Laminin binding is nearly absent in the laminin (Lam) overlay of the
patient’s muscle (C). The molecular weight of the patient’s laminin-bound band in
blot C correlates with the a-dystroglycan detected by IIH6 in blot A.
Fig. 3. Novel FKTN mutation. The relative locations of the exon 4 and exon 5
mutations are mapped on a diagram of Fukutin. Additionally, the location of the
transmembrane domain (TMD) and the conserved DxD motif are indicated.
Alignment of Fukutin amino acid sequences surrounding the novel exon 5 mutation
demonstrates conservation of the F176 residue in human, chimpanzee, dog, mouse,
rat, chicken, and frog.
354 R.L. Puckett et al. / Neuromuscular Disorders 19 (2009) 352–356laminin binding observed in the overlay assay (Fig. 2C) corre-
sponds to the low binding affinity of a-dystroglycan to IIH6
(Fig. 2A).
3.5. Mutation analysis
All six genes known to be associated with deficient glycosyla-
tion of a-dystroglycan were studied. Due to the relatively frequent
occurrence of FKRP mutations among individuals with a LGMD
phenotype, sequencing of this gene was performed first in patient
1 with normal results. Given the patient’s Japanese ancestry, muta-tion analysis for the 3 kb retrotransposon insertion mutation in the
FKTN gene was subsequently performed. Despite the fact that this
yielded negative results, it was followed by analysis of the coding
sequence and intron–exon junctions of the FKTN gene, revealing
two heterozygous missense mutations. The c.340G>A mutation,
found in exon 4, predicts an alanine (A) to threonine (T) amino acid
substitution at position 114 and the exon 5 c.527T>C variant pre-
dicts a phenylalanine (F) to serine (S) substitution at residue 176.
The c.340G>A mutation has been recently described in a pair of sib-
lings with LGMD and no mental retardation [9]. The c.527T>C var-
iant is a novel mutation. This change is predicted to be deleterious
based on the fact that it disrupts a highly conserved residue
(Fig. 3). Furthermore, a phenylalanine to serine change is not
chemically conservative and is usually pathogenic [13]. Mutation
analysis of 90 unrelated individuals failed to identify the same var-
iant. It is also not present among any of the 295 patients with FKTN
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ies revealed that the c.340G>A mutation was inherited from the
patients’ father and the c.527T>C mutation from their mother. No
mutations were detected in POMT1, POMT2, POMGnT1 or LARGE.4. Discussion
Fukuyama congenital muscular dystrophy (FCMD) is a severe
congenital muscular dystrophy occurring predominantly in Japan.
Affected children present with generalized hypotonia in infancy.
Ambulation is rare and individuals with the disorder are often bed-
ridden before they reach adolescence [2]. Severe mental retarda-
tion and brain malformations, most frequently cobblestone
lissencephaly and cerebellar cysts, are common [2,14,15]. Ophthal-
mic abnormalities, typically involving the retina, are also frequent
[16].
Classic FCMD patients have mutations in the FKTN gene, located
on chromosome 9q31 [17]. A 3-kb retrotransposon insertion muta-
tion in the 3’UTR of this gene has been identified in greater than
80% of FCMD chromosomes in the Japanese population [4,18,19].
Due to this founder mutation, FCMD is the second most common
muscular dystrophy in Japan after Duchenne Muscular Dystrophy
[2]. The 10-exon gene spans over 100 kb of genomic DNA and en-
codes a novel protein composed of 461 amino acids [20]. Identifi-
cation of the FKTN gene has allowed for molecular confirmation
in patients clinically suspected of having FCMD.
In this report, we describe two brothers of Japanese and Cauca-
sian ancestry with elevated CK, mild muscle weakness and normal
cognition who were found to carry two missense mutations in the
FKTN gene. The clinical presentation of these patients is significant
due to their onset in the toddler period and mild symptoms. Both
boys had normal early physical exams followed by slowly progres-
sive muscle involvement beginning between one and a half and
2 years of age. At ages four and six, they remain ambulant. Further-
more, the two boys have normal neurodevelopment and demon-
strate age-appropriate cognition. Additionally, they lack any
cardiac or ocular abnormalities. It is possible that cardiac involve-
ment may occur over time and therefore, the patients should con-
tinue with annual cardiac evaluations including echocardiogram or
cardiac MRI. The latter modality of heart imaging may be more
sensitive for early detection of cardiac involvement in dystrogly-
canopathy patients based on the findings of two recent studies
involving 22 LGMD2I patients [21,22].
In addition to their mild clinical presentation, our patients are
also unique from an ethnic and molecular standpoint. Their father
is of European descent and their mother, Japanese. The children,
however, do not possess the common Japanese founder mutation.
Rather, the brothers have two FKTN missense mutations, one of
which, c.527T>C, has not been previously reported. This is signifi-
cant, as the vast majority of patients reported have been either
homozygous or heterozygous for the common retrotransposon
insertion.
Due to the wide spectrum of clinical presentations and the lack
of consistent genotype–phenotype correlations, a muscle biopsy is
frequently required for the diagnosis of patients with elevated CK
and muscle weakness, as was performed in this case. The constel-
lation of myopathic features in the muscle of our patient was typ-
ical of a muscular dystrophy and the immunophenotype was
consistent with an a-dystroglycan glycosylation abnormality.
FCMD is one of a clinically and genetically heterogeneous group
of disorders, termed dystroglycanopathies, which are caused by
deficient glycosylation of a-dystroglycan. Other disorders in this
group include WWS (OMIM 236670), muscle–eye–brain disease
(MEB, OMIM 253280), congenital muscular dystrophy type IC
(MDCIC, OMIM 606612) and congenital muscular dystrophy typeID (MDCID, OMIM 608840) [23]. a-Dystroglycan is a central com-
ponent of the dystrophin–glycoprotein complex (DGC), which
serves as a high affinity cell surface receptor for laminin. The
DGC links the actin cytoskeleton to the laminins and other protein
components of the extracellular matrix. It is known to be ex-
pressed in skeletal, cardiac and smooth muscle, as well as brain
and peripheral nerve [24–26]. Mutations in several genes other
than FKTN have been identified among patients with dystroglycan-
opathies. Specifically, MEB is most often caused by mutations in
POMGnT1, WWS is commonly caused by mutations in POMT1 or
POMT2, and MDCIC and 1D are defined by mutations in FKRP and
LARGE, respectively [24]. As more patients are genetically charac-
terized, it is becoming evident that mutations in any of these six
genes may cause any of the clinical phenotypes [9].
A small number of atypically affected patients with FKTN muta-
tions have been reported within the Japanese population. In 2006,
Murakami et al. described six patients from four families, all of
whom were compound heterozygotes for the common retrotrans-
poson insertion mutation and a missense mutation, presenting
with dilated cardiomyopathy [7].
Confirmed cases of FKTN-dystroglycanopathy outside of Japan
are rare. In 2003, de Bernabé et al. described a Turkish boy of con-
sanguineous descent who was homozygous for a novel nonsense
mutation in the FKTN gene: c.345_346GC ? >CT [6]. He presented
with a WWS-like phenotype characterized by congenital hypoto-
nia, ocular abnormalities, and hydrocephalus in association with
gyral abnormalities and absence of the corpus callosum and died
at 4.5 months of age. Another Turkish patient, also with severe
brain and eye abnormalities, homozygous for a novel 1 bp insertion
mutation in exon 4 of the FKTN gene was reported in 2003 by Silan
et al. [5]. A study of fetuses with cobblestone lissencephaly from 41
families in France failed to identify any FKTN mutations [27], while
five families from a cohort of 40 with WWS (14 families from the
Middle East and 26 families from the USA or Europe) did have mu-
tant FKTN [28]. An additional four USA Ashkenazi Jewish families
with WWS were found to have a founder mutation in FKTN [29].
In 2006, a milder phenotype with a variant form of LGMD
(LGMD2L) and no brain involvement was described by Godfrey
et al. in three patients, one of Israeli origin and the other two, sib-
lings of Jewish and Indian descent, with heterozygous FKTN muta-
tions [8]. In a subsequent paper, Godfrey et al. reported two
additional non-Japanese siblings with a similar mild phenotype
and a third patient who presented with CMD but no neurological
involvement [9]. Despite the milder skeletal muscle phenotype of
these patients [8,9] and those reported by Murakami et al. [7],
muscle biopsies show a reduction in fully glycosylated a-dystro-
glycan similar to the patient presented here (Fig. 2) and severe
forms of CMD, such as FCMD and MEB [11]. This emphasizes that
immunophenotype may correlate poorly with clinical severity as
suggested by Jimenez-Mallebrera et al. in an immunohistochemis-
try study of dystroglycanopathy patients ranging from WWS to
LGMD without mental retardation [30].
One of the mutations identified in our family, c.340G>A, was
also detected in one of the sibling pairs described by Godfrey
et al. [9]. In these siblings, the mutation was inherited heterozy-
gously with a previously unreported frameshift mutation,
c.859delA, in exon 7 [9]. These children had a similar age of onset
to the siblings described in this paper, reportedly at 4 years of age
and 9 months of age. CK levels for the two sibling pairs are also
similar. The siblings reported by Godfrey et al. have had levels of
5700 and 9000 IU/L. Our patients’ levels have ranged between
1865 and 12,131 IU/L. The two sets of siblings have comparable
motor skills, characterized by the ability to ambulate indepen-
dently and even run. Calf hypertrophy, which has been docu-
mented in our patients, was also been described in one of the
siblings reported by Godfrey et al. Mild lumbar lordosis has been
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described by Godfrey et al. One of these children, however, was
reportedly born with congenital dislocation of the hip. No informa-
tion is available on the ophthalmologic or cardiac status of the pa-
tients described by Godfrey et al. Both sets of siblings have normal
intelligence.
This report further confirms FKTN mutations as a cause of LGMD
without mental retardation. It is likely that a wide variety of over-
lapping phenotypes may be caused by mutations in the FKTN gene,
and each of the other genes associated with aberrant glycosylation
of a-dystroglycan. Therefore, the diagnosis of a dystroglycanopa-
thy should be considered for all patients with clinically suspected
muscular dystrophy, regardless of the presence or absence of addi-
tional neurological and/or ocular features.
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